Document text
ACIP COVID -19 Vaccines Work Group
Robert Schechter, MD, MSc
COVID -19 ACIP Work Group Chair
Advisory Committee on Immunization Practices Meeting
April 15, 2025National Center for Immunization and Respiratory Diseases
•In August 2024, the Food and Drug Administration authorized
and approved:
-Moderna COVID -19 vaccine* in persons ≥6 months
-Novavax COVID -19 vaccine** in persons ≥12 years
-Pfizer -BioNTech COVID -19 vaccine* in persons ≥6 months 2024 –2025 COVID -19 vaccines
*Omicron JN.1 lineage, KP.2 strain
**Omicron JN.1 lineage, JN.1 strain
•Everyone aged ≥6 months should receive 2024 –2025 COVID -19 vaccination
-Children aged 6 months –4 years need multiple doses of COVID -19 vaccines to be up to date,
including at least 1 dose of 2024 –2025 COVID -19 vaccine
-People aged 5 -64 years should get 1 dose1 of 2024 -2025 COVID -19 vaccine
-People who are ≥65 years2 and people ≥6 months of age with moderate or severe
immunocompromise3 should receive a second dose of 2024 –2025 COVID -19 vaccine 6
months after their first 2024 –2025 dose (minimum interval of 2 months)
-People with moderate or severe immunocompromise may receive additional doses of
2024 –2025 COVID -19 vaccines under shared clinical decision -making (minimum interval of 2
months)2024 –2025 COVID -19 vaccine recommendations
1. People who are unvaccinated and receive Novavax COVID -19 vaccine for initial vaccination should receive 2 doses of 2024 –2025 Novavax COVID -19 vaccine
2. People who are unvaccinated and receive Novavax COVID -19 vaccine for initial vaccination should receive 2 doses of 2024 –2025 Nov avax COVID -19 vaccine
followed by a third dose of any 2024 –2025 COVID -19 vaccine dose 6 months (minimum interval 2 months) after the second dose.
3. If previously unvaccinated or receiving initial vaccination series, at least 2 doses of 2024 –2025 vaccine are recommended, an d depending on vaccination history
more may be needed. This additional 2024 –2025 vaccine dose is recommended 6 months (minimum interval 2 months) after completion of initial vaccination series.
Provisional Weekly COVID -19 Deaths in the United States
Reported to CDC, by Week October 2021 –March 2025
https://covid.cdc.gov/covid -data -tracker/#trends_weeklydeaths_select_00
Accessed April 4, 202505,00010,00015,00020,00025,000
October November December January February March April May June July August SeptemberWeekly Deaths
Surveillance Month2021-2022 2022-2023 2023-2024 2024-2025
Weekly rates of COVID -19 associated hospitalizations
by season – COVID -NET
https://www.cdc.gov/covid/php/covid -net/index.html
Accessed April 4 , 2025
Preliminary Estimates of Disease Burden,
October 1, 2024 through March 22, 2025
Disease Illnesses Outpatient
VisitsHospitalizations Deaths
COVID -191 7.7 – 13.5
Million1.9 – 3.2
Million220,000 –
370,00026,000 –
43,000
Influenza2 44 – 76
Million20 – 34
Million580,000 – 1.2
Million25,000 –
120,000
1 https://www.cdc.gov/covid/php/surveillance/burden -estimates.html
2 https://www.cdc.gov/flu -burden/php/data -vis/2024 -2025.html
Accessed April 4, 2025
Current season week ending date refers to the 2024 -2025 season only. For the 2023 -2024 season, the corresponding week is represe nted.
2024 -2025 vaccines were available starting August 22, 2024. 2023 -2024 vaccines were available starting September 12, 2023.
https://www.cdc.gov/covidvaxview/weekly -dashboard/adult -vaccination -coverage.html
Accessed April 4, 2025 COVID -19 vaccination coverage among adults 18 years
and older, 2023 –2024 through 2024 –2025
ACIP COVID -19 Work Group Meeting Review
November 2024 – April 2025
•Considerations for a risk -based and universal vaccine recommendation for the
2025 –2026 COVID -19 vaccines
•COVID -NET data for those with and
without risk factors
•COVID -19 mortality
•COVID -19 vaccine hesitancy and
uptake
•COVID -19 vaccine safety and
effectiveness•Moderna mRNA -1283 COVID -19
vaccine candidate
•Seroprevalence of SARS -CoV-2
•Post -COVID conditions (Long COVID)
•Multisystem Inflammatory Syndrome
in Children (MIS -C)
•Feedback from liaison organizations
Introduction Dr. Robert Schechter (ACIP, WG Chair)
Moderna mRNA -1283 COVID -19
vaccine candidateDr. Bishoy Rizkalla
Epidemiology and risk factors for
COVID -19 hospitalizationsDr. Fiona Havers
Vaccine effectiveness update Dr. Ruth Link -Gelles
Work Group Considerations for use
of 2025 –2026 COVID -19 vaccinesDr. Lakshmi PanagiotakopoulosAgenda: April 15, 2025
•Today’s meeting: Update on ongoing review of considerations
for use of 2025 –2026 COVID -19 vaccines
•Spring : Anticipated FDA Vaccines and Related Biological
Products Advisory Committee (VRBPAC) meeting to discuss and
make recommendations on strain selection for 2025 –2026
COVID -19 vaccines
•June ACIP meeting : Discussion and vote on recommended use
of the 2025 –2026 vaccine
•Late summer/early fall : Anticipated 2025 –2026 COVID -19
vaccine availabilityPreliminary Timeline, 2025 –2026 COVID -19
Vaccines
Work Group members
ACIP members
•Robert Schechter (chair)
•Noel Brewer
•Oliver Brooks
•George Kuchel
•Keipp Talbot
Ex-officio/government members
•BARDA: Christine Oshansky
•CDC: Alan Lam
•FDA: Adam Spanier, Rachel Zhang
•IHS: Uzo Chukwuma
•NIH: Chris Roberts
CDC co -Leads
•Lakshmi Panagiotakopoulos
•Lauren RoperLiaisons
•AAFP: Jonathan Temte
•AAP: Sean O’Leary
•ACOG: Naima Joseph,
Laura Riley (alternate)
•ACP: Jason Goldman
•AGS: Ken Schmader
•AIM: Heather Roth
•AMA: Sandra Fryhofer
•ANA: Ruth Francis
•APhA : Richard Dang
•ASTHO: Marcus Plescia
•CSTE: Paul Cieslak ,
Christine Hahn
•IDSA: James McAuley
•NACCHO: Matt ZahnLiaisons, cont’d
•NACI: Eva Wong, Matthew
Tunis (alternate)
•NFID: Robert Hopkins, Bill
Schaffner (alternate)
•SHEA: Preeti Mehrotra,
Marci Drees (alternate)
Consultants
•Ed Belongia
•Hank Bernstein
•Matthew Daley
•Lisa Jackson
•Jennifer Nelson
•Stanley Perlman
•Peter Szilagyi
CDC participants
•Amadea Britton
•Mary Chamberland
•Fatimah Dawood
•Nicole Dowling
•Jonathan Duffy
•Kristen Folsom
•Molly Gaines -McCollom
•Julianne Gee
•Monica Godfrey
•Susan Goldstein
•Lisa Grohskopf
•Demorah Hayes
•Suzanne Heitfeld•Michele Hlavsa
•Jefferson Jones
•Ruth Link -Gelles
•Jessica MacNeil
•Josephine Mak
•Seth Abram Meador
•Michael Melgar
•Sarah Meyer
•Noelle -Angelique Molinari
•Danielle Moulia
•Ismael Ortega -Sanchez
•Manisha Patel
•Pragna Patel•Amanda Payne
•Jamison Pike
•Hannah Rosenblum
•Sierra Scarbrough
•John Su
•Diya Surie
•Natalie Thornburg
•Melinda Wharton
•Trang Wisard
•JoEllen Wolicki
For more information, contact CDC
1-800-CDC-INFO (232 -4636)
TTY: 1 -888-232-6348 cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the official
position of the U.S. Centers for Disease Control and Prevention.